 NEEDHAM, Mass., Nov. 20, 2020 GLOBE NEWSWIRE -- Chiasma, Inc. NASDAQ: CHMA, a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that it will host an expert panel on acromegaly and the results from its recently completed MPOWERED Phase 3 clinical trial on Monday, November 30, 2020 at 11:00 am Eastern Time. 